Up-to-date news about Intravacc
Stay informed about the latest developments in our mission to pioneer transformative vaccines with up-to-date corporate communications. Get the latest news on our development and business milestones, as well as industry insights, partnership announcements, and corporate reports.
![polio polio](/fileadmin/_processed_/5/9/csm_polio_4b7c5e6c39.jpg)
Intravacc’s Sabin Inactivated Polio vaccine (sIPV), outlicensed to LG Chem, receives WHO prequalification
![press 18 press 18](/fileadmin/_processed_/1/c/csm_press-18_19dd77b152.jpg)
Intravacc announces completion of formulation and manufacturing process development of PRV-101 vaccine candidate for Provention Bio
![press 20 press 20](/fileadmin/_processed_/7/6/csm_press-20_6d90769fda.jpg)
Cristal Therapeutics and Intravacc Announce Strategic Collaboration to Advance Novel Vaccine Platforms
![corporate 7 corporate 7](/fileadmin/01-Website/02-News/2023/Corporate/corporate-7.jpg)
Intravacc appoints three Supervisory Board members
![](/fileadmin/_processed_/4/1/csm_corporate-5_330417d8ce.jpg)
Dutch vaccine developer Intravacc becomes public shareholding company effective 1st January 2021
![Shigellois Shigellois](/fileadmin/_processed_/0/b/csm_Shigellois_645bb5c73c.jpg)
Intravacc publishes positive phase I Shigella conjugate vaccine data
![](/fileadmin/_processed_/2/b/csm_virgil-news_f553344513.jpg)
Intravacc appoints Prof. Dr. Virgil Schijns as Chief Scientific Officer
![corporate 12 corporate 12](/fileadmin/_processed_/f/1/csm_corporate-12_5878594102.jpg)
Intravacc 2.0
![](/fileadmin/_processed_/1/6/csm_contracts-4_10c6487ce7.jpg)
Intravacc Receives US NIH/NIAID Contract to Develop Enterovirus D68 Vaccine
![press 19 press 19](/fileadmin/_processed_/c/e/csm_press-19_fc4447065f.jpg)
Intravacc and Celonic to Develop and Produce a Novel COVID-19 Vaccine